Skip to content

Bile suppletion as adjuvant therapy in the treatment of iatrogenic bile duct injury after cholecystectomy: a bitter necessity?

Bile suppletion as adjuvant therapy in the treatment of iatrogenic bile duct injury after cholecystectomy: a bitter necessity? - Bitter necessity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30074
Enrollment
40
Registered
2006-07-05
Start date
2006-06-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile duct damage Bile duct injury

Interventions

One group receives the drained bile to a maximum of 900 ml/day in three equal portions. The control group receives no suppletion of the drained bile.

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Older than 18 years of age -Total or partial iatrogenic damage of the biliary tract after cholecystectomy, leading to biliary drainage and subsequent need for surgical reconstruction. -Patients are included in the study after signing informed consent.

Exclusion criteria

Exclusion criteria: -Malignancies of the biliary tract -Malignancies of the pancreas -Unwillingness to receive bile restitution -Cholangitis (bacterial contamination of the bile) -Insufficient bile-drain production

Design outcomes

Primary

MeasureTime frame
Body weight expressed in Kilogrammes.

Secondary

MeasureTime frame
- Body Mass Index (BMI), - Body composition expressed in fat-mass, lean body mass, handgrip strength and mid-arm muscular circumference (MAMC), - Nutritional intake expressed in macronutrients, micronutrients and fluids, - Stability of Cl, K, Na, Ca, Fe and cholesterol plasma values. - Quality of life measured by SF-36 and GiQLi, - Incidence of nausea, intestinal cramps, intestinal pain and diarrhoea and sepsis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)